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Performance of electrophysiologic study in an 
asymptomatic patient with type 2 intermittent  
Brugada syndrome: To do or not to do 
 
Abstract 
Background: Brugada syndrome (BrS) is an inherited channelopathy, which is associated 
with sudden cardiac death due to rapid polymorphic VT or VF. There is no definite 
consensus regarding the management of asymptomatic patients. Some experts advocate 
close follow-up; others propose the programmed stimulation for risk stratification. We 
aimed to evaluate the benefit of complete atrial and ventricular stimulation in patients with 
BrS and palpitation. 
Case Presentation: A 30-year-old man was admitted to our hospital because of a family 
history of sudden cardiac death (SCD) at age less than 45 years. He complained of self-
terminated episodes of palpitation with no history of syncope. Baseline ECG showed 
incomplete right bundle branch block (RBBB) and saddle-back-like ST deviation in V1. 
Flecainide challenge test (FCT) revealed Brugada pattern. Complete EPS was done for 
evaluation of VT/VF inducibility and probable concomitant supraventricular arrhythmias. 
Programmed atrial stimulation showed inducible typical slow-fast AVNRT with AH jump 
75 msec. Successful slow pathway ablation was done. There was no inducible ventricular 
arrhythmia. 
Conclusions: Patients with drug-induced BrS, positive family history of SCD and also 
episodes of palpitation, benefit from complete EPS. However, ICD implementation is not 
recommended in asymptomatic patients with drug-induced BrS and negative EPS for 
ventricular stimulation. 
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Brugada syndrome (BrS) is an autosomal dominant disorder characterized by ST 
segment elevation in right precordial leads and an increased risk of sudden cardiac death 
(SCD) (1). The prevalence of Brugada ECG is higher in Asia than in the United States and 
Europe (2). The main cause of sudden death in this syndrome is ventricular fibrillation 
(VF). There is not definitive treatment modality that reliably and totally prevents 
ventricular fibrillation in this syndrome. Prevention of this lethal arrhythmia before it 
causes SCD is cardinal. Guideline-based implementation of an implementable cardioverter 
defibrillator (ICD) is recommended in selected cases
3
. In this case report, an asymptomatic 
patient with Brugada syndrome was admitted due to self-limited palpitation and was 
evaluated for malignant ventricular arrhythmias.  
 
Case Presentation 
A 30-year-old man was admitted to our hospital because of a family history of sudden 
cardiac death in two uncles and one cousin, and suspicious ECG pattern, in favor of BrS. 
He also complained of frequent self-terminated episodes of palpitation in the past 3 years. 
Frequency and duration of palpitation attacks increased in the past 4 months. 
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He took propranolol whenever the attacks started, but as 
he described; ‘’nothing just happens with this pill!’’. There 
was no episode of syncope, loss of conscious in his lifetime. 
Physical examination and lab results were normal. Both 
coronary angiogram and echocardiography revealed no 
structural heart disease. 24-hour holter monitoring was 
unremarkable. Baseline ECG showed incomplete RBBB and 
saddle-back-like ST deviation in V1. Figure1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Baseline surface ECG. 
 
To confirm the diagnosis, the patient underwent 
Flecainide challenge test (FCT) in coronary care unit. After 
informed consent from the patient, 400 mg of oral Flecainide 
was used to perform the test.12-lead ECG was recorded 
every 30 min for 3 hours, and the patient was under precise 
cardiac monitoring for 6 hours. Type-2 BrS was manifested 
1 hour after the test, (figure 2). The patient had no complaint 
during FCT.  
These changes disappeared 5 hours after the beginning of 
the test and reappeared spontaneously in tomorrow morning. 
Hence, an intermittent form of BrS was suspected in this 
patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Surface ECG after Flecainide Challenge Test. 
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Based on history of palpitation and also family history of 
SCD, the patient underwent complete EPS. There was no 
inducible VF or VT in ventricular stimulation. However, 
programmed atrial stimulation showed inducible typical 
slow-fast AVNRT with AH jump 75 msec. Successful slow 
pathway ablation was done (figures 3 and 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Surface ECG during episode of palpitation                  Figure 4. EP tracing. Narrow complex Short RP tachycardia 
 
Discussion 
SCD is attributed to dangerous ventricular arrhythmia in 
these patients. Based on accepted guidelines, ICD 
implementation in symptomatic BrS who are survivors of an 
aborted cardiac arrest and/or have documented spontaneous 
sustained VT is recommended and should be considered in 
patients with a spontaneous diagnostic type I ECG pattern 
and history of syncope. The question about the role of 
complete EPS in newly diagnosed BrS is still up for 
discussion. 
The association between BrS and supraventricular 
arrhythmias was first described in 2001 (4). Dysfunction of 
sodium channel that causes malignant arrhythmias in BrS, is 
attributed to mutation of SCNA5 gene (5). In recent studies, 
the idea about extension of this and other sodium channel 
mutations to atrial myocardium and concomitant 
supraventricular re-entry type arrhythmias, is on the table 
nowadays (6, 7). Patients with BrS may experience benign 
episodes of self-terminated palpitation without syncope or 
aborted SCD. Idiopathic VF and SVT may both be present in 
BrS.  
Routine EPS as a tool for risk stratification in 
asymptomatic patients is still a challenging subject. The 
second consensus report
8
 recommends EPS in asymptomatic 
patients with spontaneous type 1 ECG and ICD implantation 
be recommended if the EPS is positive (class 2A) and a close 
follow up, if the EPS is negative. If the patient is 
asymptomatic and BrS ECG changes appeared just after a 
drug challenge, ICD implantation is indicated only if EPS is 
positive (class 2B) (3). 
There is no consensus on the value of the EPS in 
predicting outcome. While Brugada et al. considered 
sustained ventricular arrhythmia as a strong predictor of 
SCD (9) while others do not. The PRELUDE (programmed 
electrical stimulation predictive value) (10) registry failed to 
support the view that lack of indelibility has negative 
predictive value in BrS. The FINGER (France, Italy, 
Netherlands, Germany) registry (11), found that inducibility 
of sustained ventricular arrhythmias was significantly 
associated with a shorter time to first arrhythmic event in the 
univariate analysis, but in the multivariate analysis, it did not 
predict future arrhythmic events. 
Our patient was asymptomatic and ECG changes were 
evident after Flecainide challenge test (FCT). According to 
the guidelines of the Cardiac Society of Australia and New 
Zealand (3), EPS is indicated (class 2B), and in the case of 
positive EPS, ICD implementation should be considered. We 
performed EPS; no ventricular arrhythmia was induced, 
hence, we did not recommend ICD to the patient. On the 
other hand, based on aforementioned guidelines, EPS is 
recommended for investigation of associated SVT. Chief 
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complaint of bothering palpitation in this case, made us to 
perform a complete EPS. So, one may conclude that EPS is 
logical when positive FCT and/or history of palpitation are 
present in a patient with BrS. The latest consensus on BrS in 
2015 (12), emphasized on EPS in asymptomatic patients 
with positive family history, but data about patients with 
negative family history is still lacking (13). These guidelines 
also recommend ICD for patients with all these three criteria; 
1) spontaneous or drug-induced type 1 BrS, 2) Positive 
family history of SCD and 3) inducible VF/VT in EPS.  
In conclusion, in this case, based on his positive family 
history of SCD and also episodes of palpitation, he benefits 
from complete EPS. Since, he did not fulfill all the branches 
of the above triad; he is not a good candidate for ICD 
implementation. 
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